While our framework leverages T1-weighted MRI scans for Alzheimer’s disease (AD) classification, multimodal approaches integrating neuropsychological tests and laboratory biomarkers, such as tau protein levels, offer potential to enhance diagnostic precision, particularly for early-stage detection. The gene discussed is MAPT; the disease is Alzheimer disease.